{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,24]],"date-time":"2025-05-24T04:10:02Z","timestamp":1748059802735,"version":"3.41.0"},"reference-count":21,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["lipidjournal.com","clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Clinical Lipidology"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1016\/j.jacl.2025.03.008","type":"journal-article","created":{"date-parts":[[2025,3,22]],"date-time":"2025-03-22T12:08:13Z","timestamp":1742645293000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Prevention of acute systemic reaction during LDL apheresis post COVID-19 by icatibant pretreatment"],"prefix":"10.1016","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-2573-182X","authenticated-orcid":false,"given":"Lauren R.","family":"Davidson","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naz","family":"Baecher","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brian","family":"Cheung","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Scott","family":"McIntosh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8131-640X","authenticated-orcid":false,"given":"Theresa A.","family":"Bingemann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4525-7585","authenticated-orcid":false,"given":"Robert C.","family":"Block","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jacl.2025.03.008_bib0001","unstructured":"About Familial Hypercholesterolemia | Heart Disease, Family Health history, and familial hypercholesterolemia. [Accessed September 17, 2024. Available from: https:\/\/www.cdc.gov\/heart-disease-family-history\/about\/about-familial-hypercholesterolemia.html#:~:text=A%20genetic%20change%20in%20only,one%20FH%2Dcausing%20genetic%20change."},{"issue":"12","key":"10.1016\/j.jacl.2025.03.008_bib0002","doi-asserted-by":"crossref","DOI":"10.1161\/ATV.0000000000000177","article-title":"Lipoprotein apheresis: utility, outcomes, and implementation in clinical practice: a scientific statement from the American Heart Association","volume":"44","author":"Gianos","year":"2024","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"8","key":"10.1016\/j.jacl.2025.03.008_bib0003","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCINTERVENTIONS.119.008933","article-title":"Plaque regression and endothelial progenitor cell mobilization with intensive lipid elimination regimen (PREMIER)","volume":"13","author":"Banerjee","year":"2020","journal-title":"Circ Cardiovasc Interv"},{"issue":"3","key":"10.1016\/j.jacl.2025.03.008_bib0004","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1002\/jca.21884","article-title":"Establishing low-density lipoprotein apheresis tolerability in patients with prior anaphylactoid reactions to lipoprotein apheresis using magnesium sulfate","volume":"36","author":"Alexander","year":"2021","journal-title":"J Clin Apher"},{"issue":"10","key":"10.1016\/j.jacl.2025.03.008_bib0005","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1016\/j.imbio.2016.06.064","article-title":"LDL apheresis activates the complement system and the cytokine network, whereas PCSK9 inhibition induces no inflammatory response","volume":"221","author":"Hovland","year":"2016","journal-title":"Immunobiology"},{"issue":"4","key":"10.1016\/j.jacl.2025.03.008_bib0006","doi-asserted-by":"crossref","first-page":"1734","DOI":"10.1016\/j.jaip.2020.10.049","article-title":"Case report: prevention of apheresis reactions with icatibant","volume":"9","author":"Kirkpatrick","year":"2021","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"8912","key":"10.1016\/j.jacl.2025.03.008_bib0007","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1016\/S0140-6736(94)92978-5","article-title":"Prevention with icatibant of anaphylactoid reactions to ACE inhibitor during LDL apheresis","volume":"343","author":"Davidson","year":"1994","journal-title":"Lancet"},{"issue":"7","key":"10.1016\/j.jacl.2025.03.008_bib0008","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1136\/hrt.2008.162909","article-title":"Controversies in familial hypercholesterolaemia: recommendations of the NICE Guideline Development Group for the identification and management of familial hypercholesterolaemia","volume":"95","author":"Minhas","year":"2009","journal-title":"Heart"},{"key":"10.1016\/j.jacl.2025.03.008_bib0009","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.atherosclerosis.2018.04.040","article-title":"Coronary heart disease mortality in treated familial hypercholesterolaemia: update of the UK Simon Broome FH register","volume":"274","author":"Humphries","year":"2018","journal-title":"Atherosclerosis"},{"issue":"6","key":"10.1016\/j.jacl.2025.03.008_bib0010","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1253\/circj.CJ-20-0901","article-title":"Clinical diagnostic criteria of familial hypercholesterolemia: a comparison of the Japan Atherosclerosis Society and Dutch Lipid Clinic Network criteria","volume":"85","author":"Tada","year":"2021","journal-title":"Circ J"},{"issue":"10","key":"10.1016\/j.jacl.2025.03.008_bib0011","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1016\/j.acvd.2015.04.003","article-title":"Dutch Lipid Clinic Network low-density lipoprotein cholesterol criteria are associated with long-term mortality in the general population","volume":"108","author":"S\u00e9guro","year":"2015","journal-title":"Arch Cardiovasc Dis"},{"issue":"1","key":"10.1016\/j.jacl.2025.03.008_bib0012","doi-asserted-by":"crossref","first-page":"e13","DOI":"10.1016\/j.jacl.2021.09.019","article-title":"Case study of hypertriglyceridemia from COVID-19 Pfizer-BioNTech vaccination in a patient with familial hypercholesteremia","volume":"16","author":"Cheung","year":"2022","journal-title":"J Clin Lipidol"},{"issue":"4","key":"10.1016\/j.jacl.2025.03.008_bib0013","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1111\/j.1744-9987.1998.tb00119.x","article-title":"Changes in plasma levels of cyclic nucleotides during low-density lipoprotein apheresis","volume":"2","author":"Kojima","year":"1998","journal-title":"Therapeutic Apheresis"},{"issue":"2","key":"10.1016\/j.jacl.2025.03.008_bib0014","doi-asserted-by":"crossref","DOI":"10.1111\/dth.14753","article-title":"Cutaneous manifestations of COVID-19: an unusual presentation with edematous plaques and pruritic, erythematous papules, and comment on the role of bradykinin storm and its therapeutic implications","volume":"34","author":"Kroumpouzos","year":"2021","journal-title":"Dermatol Ther"},{"issue":"10","key":"10.1016\/j.jacl.2025.03.008_bib0015","doi-asserted-by":"crossref","first-page":"9915","DOI":"10.1007\/s11033-022-07539-2","article-title":"A comprehensive review on current understanding of bradykinin in COVID-19 and inflammatory diseases","volume":"49","author":"Rex","year":"2022","journal-title":"Mol Biol Rep"},{"issue":"6","key":"10.1016\/j.jacl.2025.03.008_bib0016","doi-asserted-by":"crossref","DOI":"10.1111\/dth.15461","article-title":"A systematic review on mucocutaneous presentations after COVID-19 vaccination and expert recommendations about vaccination of important immune-mediated dermatologic disorders","volume":"35","author":"Seirafianpour","year":"2022","journal-title":"Dermatol Ther"},{"key":"10.1016\/j.jacl.2025.03.008_bib0017","article-title":"Coronavirus disease-19 infection and angioedema in African Americans: a case series","volume":"24","author":"Martinez Manzano","year":"2022","journal-title":"Otolaryngol Case Rep"},{"issue":"11","key":"10.1016\/j.jacl.2025.03.008_bib0018","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1164\/rccm.202006-2223LE","article-title":"Angioedema in African American patients hospitalized for COVID-19","volume":"202","author":"Batarseh","year":"2020","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jacl.2025.03.008_bib0019","doi-asserted-by":"crossref","first-page":"1","DOI":"10.7554\/eLife.59177","article-title":"A mechanistic model and therapeutic interventions for COVID-19 involving a RAS-mediated bradykinin storm","volume":"9","author":"Garvin","year":"2020","journal-title":"Elife"},{"issue":"7","key":"10.1016\/j.jacl.2025.03.008_bib0020","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.1253\/circj.CJ-12-1163","article-title":"Increased tissue angiotensin-converting enzyme activity impairs bradykinin-induced dilation of coronary arterioles in obesity","volume":"77","author":"Feher","year":"2013","journal-title":"Circ J"},{"issue":"2","key":"10.1016\/j.jacl.2025.03.008_bib0021","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.ccl.2015.02.002","article-title":"Lipoprotein apheresis","volume":"33","author":"Moriarty","year":"2015","journal-title":"Cardiol Clin"}],"container-title":["Journal of Clinical Lipidology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1933287425000649?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1933287425000649?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,5,24]],"date-time":"2025-05-24T03:33:48Z","timestamp":1748057628000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1933287425000649"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3]]},"references-count":21,"alternative-id":["S1933287425000649"],"URL":"https:\/\/doi.org\/10.1016\/j.jacl.2025.03.008","relation":{},"ISSN":["1933-2874"],"issn-type":[{"type":"print","value":"1933-2874"}],"subject":[],"published":{"date-parts":[[2025,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Prevention of acute systemic reaction during LDL apheresis post COVID-19 by icatibant pretreatment","name":"articletitle","label":"Article Title"},{"value":"Journal of Clinical Lipidology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jacl.2025.03.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 National Lipid Association. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}